NextCure Inc (NXTC)
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. Its pipeline includes LNCB74, a B7-H4-targeted antibody-drug conjugate designed to kill tumors, along with NC410, a fusion protein based on LAIR-2 intended to counter immune suppression mediated by LAIR-1. The company is also advancing NC525, a LAIR-1 antibody being studied for acute myeloid leukemia, NC181, a humanized antibody targeting ApoE4 for Alzheimer’s disease, NC605, an antibody directed at Siglec-15 and related chronic bone conditions, and SIM0505, an ADC targeting CDH6 for solid tumors. Incorporated in 2015, NextCure is headquartered in Beltsville, Maryland, and its common stock trades on NASDAQ under the symbol NXTC.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NXTC
|
$7.15
|
45.6% Upside
|
Undervalued
|
$20
|
306.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-0.3x
|
0.7x
|
—
|
19.505 M
|
-7.275 M
|
20.1%
|
62.6%
|
-38.2
|
—
|
91.4%
|
